246 related articles for article (PubMed ID: 32044284)
1. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity?
Cordeiro A; Costa R; Andrade N; Silva C; Canabrava N; Pena MJ; Rodrigues I; Andrade S; Ramalho A
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):394-402. PubMed ID: 32044284
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease.
Wang X; Rao H; Liu F; Wei L; Li H; Wu C
Cells; 2021 Nov; 10(12):. PubMed ID: 34943809
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
4. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
Cimini FA; Barchetta I; Carotti S; Bertoccini L; Baroni MG; Vespasiani-Gentilucci U; Cavallo MG; Morini S
World J Gastroenterol; 2017 May; 23(19):3407-3417. PubMed ID: 28596677
[TBL] [Abstract][Full Text] [Related]
5. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA
Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460
[TBL] [Abstract][Full Text] [Related]
6. Adipose type I interferon signalling protects against metabolic dysfunction.
Wieser V; Adolph TE; Grander C; Grabherr F; Enrich B; Moser P; Moschen AR; Kaser S; Tilg H
Gut; 2018 Jan; 67(1):157-165. PubMed ID: 28011892
[TBL] [Abstract][Full Text] [Related]
7. [Pathogenesis of non-alcoholic fatty liver disease].
Anty R; Gual P
Presse Med; 2019 Dec; 48(12):1468-1483. PubMed ID: 31767252
[TBL] [Abstract][Full Text] [Related]
8. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.
Qureshi K; Abrams GA
World J Gastroenterol; 2007 Jul; 13(26):3540-53. PubMed ID: 17659704
[TBL] [Abstract][Full Text] [Related]
9. Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease.
Darci-Maher N; Alvarez M; Arasu UT; Selvarajan I; Lee SHT; Pan DZ; Miao Z; Das SS; Kaminska D; Örd T; Benhammou JN; Wabitsch M; Pisegna JR; Männistö V; Pietiläinen KH; Laakso M; Sinsheimer JS; Kaikkonen MU; Pihlajamäki J; Pajukanta P
EBioMedicine; 2023 Jun; 92():104620. PubMed ID: 37224770
[TBL] [Abstract][Full Text] [Related]
10. Dietary sucrose regulates the expression of the Cd36 gene in hepatic tissue of rats with obesity and Non Alcoholic Fatty Liver Disease (NAFLD).
Castro RQ; Soto Rodriguez I; Deschamps Lago RA; Pagola PG; Rodriguez Antolin J; Peres Quintal A; Rivera JR; Aguilera AA
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Jun; 162(2):99-106. PubMed ID: 29765172
[TBL] [Abstract][Full Text] [Related]
11. The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease.
Romero-Zerbo SY; García-Fernández M; Espinosa-Jiménez V; Pozo-Morales M; Escamilla-Sánchez A; Sánchez-Salido L; Lara E; Cobo-Vuilleumier N; Rafacho A; Olveira G; Rojo-Martínez G; Gauthier BR; González-Mariscal I; Bermúdez-Silva FJ
Front Endocrinol (Lausanne); 2020; 11():103. PubMed ID: 32210914
[No Abstract] [Full Text] [Related]
12. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?
Finelli C; Tarantino G
World J Gastroenterol; 2013 Feb; 19(6):802-12. PubMed ID: 23430039
[TBL] [Abstract][Full Text] [Related]
13. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Zhang X; Ji X; Wang Q; Li JZ
Protein Cell; 2018 Feb; 9(2):164-177. PubMed ID: 28643267
[TBL] [Abstract][Full Text] [Related]
14. Macrophage Subsets in Obesity, Aligning the Liver and Adipose Tissue.
Remmerie A; Martens L; Scott CL
Front Endocrinol (Lausanne); 2020; 11():259. PubMed ID: 32411096
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.
Kořínková L; Pražienková V; Černá L; Karnošová A; Železná B; Kuneš J; Maletínská L
Front Endocrinol (Lausanne); 2020; 11():597583. PubMed ID: 33324348
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease.
Ishtiaq SM; Rashid H; Hussain Z; Arshad MI; Khan JA
Rev Endocr Metab Disord; 2019 Sep; 20(3):253-261. PubMed ID: 31656991
[TBL] [Abstract][Full Text] [Related]
17. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
18. Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity.
Angelini G; Castagneto-Gissey L; Casella-Mariolo J; Caristo ME; Russo MF; Lembo E; Verrastro O; Stefanizzi G; Marini PL; Casella G; Bornstein SR; Rubino F; Mingrone G
Am J Physiol Gastrointest Liver Physiol; 2020 Oct; 319(4):G502-G511. PubMed ID: 32812775
[TBL] [Abstract][Full Text] [Related]
19. Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD.
Gart E; Souto Lima E; Schuren F; de Ruiter CGF; Attema J; Verschuren L; Keijer J; Salic K; Morrison MC; Kleemann R
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577415
[TBL] [Abstract][Full Text] [Related]
20. Targeting adipose tissue inflammation to treat the underlying basis of the metabolic complications of obesity.
Goran MI; Alderete TL
Nestle Nutr Inst Workshop Ser; 2012; 73():49-60; discussion p61-6. PubMed ID: 23128765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
